The Biggest Risk in In Vivo Therapeutic Engineering Is What We Cannot See
in vivo
In vivo therapeutic engineering is often framed as the next logical evolution of ex vivo cell and gene therapy. By eliminating complex manufacturing steps and enabling direct delivery of therapeutic payloads into the body, these approaches promise broader access, faster treatment timelines, and potentially lower cost.